<DOC>
	<DOCNO>NCT02669940</DOCNO>
	<brief_summary>This study seek ass effectiveness , patient report outcome , work productivity healthcare resource utilization interferon-free regimen Paritaprevir ( PTV ) /ritonavir ( r ) - Ombitasvir ( OBV ) , ± Dasabuvir ( DSV ) , ± Ribavirin chronic hepatitis C ( CHC ) participant real life set across clinical practice population .</brief_summary>
	<brief_title>Real World Evidence Effectiveness Paritaprevir/r - Ombitasvir , ± Dasabuvir , ± Ribavirin Patients With Chronic Hepatitis C Russian Federation - An Observational , Multi-Center Study</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Patients eligible observation cohort follow applies : Treatmentnaïve experience adult male female patient confirm CHC , genotype 1 , receive combination therapy interferonfree ABBVIE REGIMEN ± RBV accord standard care line current local label If RBV coadministered ABBVIE REGIMEN , prescribe line current local label ( special attention contraception requirement contraindication pregnancy ) Patients must voluntarily sign date inform consent prior inclusion study Patient must participate intend participate concurrent interventional therapeutic trial Patient must participate intend participate concurrent interventional therapeutic trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Ombitasvir</keyword>
	<keyword>Dasabuvir</keyword>
	<keyword>Paritaprevir</keyword>
</DOC>